ArticleMolecules (Basel, Switzerland)2018
Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Aptamer targeting proprotein convertase subtilisin/kexin type 9:Research in pharmaceutical sciences · 2026Article
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy.Clinical and experimental medicine · 2025Review
- Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia.Molecular therapy. Nucleic acids · 2023Article
- Targeted therapy for cisplatin-resistant lung cancer via aptamer-guided nano-zinc carriers containing USP14 siRNA.MedComm · 2023Article
- Article
- bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.International journal of molecular sciences · 2023Review
- Review
- Novel Approach to Overcome Defects of Cell-SELEX in Developing Aptamers against Aspartate β-Hydroxylase.ACS omega · 2021Article
- Accomplishment of one-step specific PCR and evaluated SELEX process by a dual-microfluidic amplified system.Biomicrofluidics · 2021Article
- The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.Frontiers in immunology · 2021Review
- Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy.Molecular biology reports · 2021Article
- Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.International journal of molecular sciences · 2020Review
- Aptamer-based approaches forResearch in pharmaceutical sciences · 2020Review
- Nucleic Acid Aptamer: A Novel Potential Diagnostic and Therapeutic Tool for Leukemia.OncoTargets and therapy · 2019Review
- Aptamers as Diagnostic Tools in Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The B-lymphocyte antigen (CD20) is a suitable target for single-stranded (ss) nucleic acid oligomer (aptamers). The aim of study was selection and characterization of a ssDNA aptamer against CD20 using Cell-Systematic Evolution of Ligands by Exponential Enrichment (Cell-SELEX). The cDNA clone of CD20 (pcDNA-CD20) was transfected to human embryonic kidney (HEK293T) cells. Ten rounds of Cell-SELEX was performed on recombinant HEK-CD20 cells. The final eluted ssDNA pool was amplified and ligated in T/A vector for cloning. The plasmids of positive clones were extracted, sequenced and the secondary structures of the aptamers predicted using DNAMAN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.